Doximity, Inc. ($DOCS) Stock Forecast: Up 5.0% Today

What is Doximity, Inc.?

Doximity Inc-Class A (NYSE:DOCS) is a tech-health software company specialized in facilitating collaboration among healthcare professionals. The company has recently seen fluctuations in its stock price.

Why is Doximity, Inc. going up?

DOCS stock is up 5.0% on Feb 10, 2026 15:20

• After exceeding expectations in revenue and EPS for Q3, Doximity's shares experienced a significant drop following a conservative revenue outlook for the fiscal fourth quarter, leading to a bearish trend in the market.
• The stock's recent decline is linked to industry-wide apprehensions regarding the impact of AI technology in the tech-health software segment, despite noteworthy growth in revenue, expansion of customer base, and initiation of a new stock repurchase plan.
• The disparity between Doximity's robust historical performance, subdued future growth projections, and elevated P/E ratio has heightened investment risks, contributing to the downward trajectory of the stock.
• In conclusion, while facing challenges related to market sentiment and valuation uncertainties, Doximity's strategic endeavors such as integrating AI products and enhancing user engagement may present favorable long-term investment prospects.

DOCS Price Chart

DOCS Technical Analysis

DOCS News

Doximity Inc-Class A (NYSE:DOCS) Plummets on Weak Revenue Outlook Despite Q3 Beat

Doximity Inc-Class A (NYSE:DOCS) reported a Q3 beat on revenue and EPS, surpassing analyst expectations. However, the company's shares plummeted in after-hours trading due to a fiscal fourth-quarter revenue outlook that fell short of Wall Street estimates. This guidance miss overshadowed strong user engagement, AI product adoption, and a new $500 million stock repurchase program.

https://www.chartmill.com/news/DOCS/Chartmill-41310-Doximity-Inc-Class-A-NYSEDOCS-Plummets-on-Weak-Revenue-Outlook-Despite-Q3-Beat

Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%

Doximity, Inc. (NYSE:DOCS) shares have fallen 27% in the last month, contributing to a 43% drop over the past year. Despite strong recent earnings growth of 44% last year and 82% over three years, its current P/E ratio of 24.8x is high given analyst forecasts for only 1.0% annual growth, significantly less than the market's projected 12%. This disconnect between past performance, future growth estimates, and its elevated P/E ratio suggests potential risks for investors.

https://www.sahmcapital.com/news/content/doximity-incs-nysedocs-popularity-with-investors-under-threat-as-stock-sinks-27-2026-02-06

Doximity Announces Fiscal 2026 Third Quarter Financial Results

Doximity (NYSE: DOCS) announced its fiscal 2026 third-quarter financial results, reporting total revenues of $185.1 million, a 10% year-over-year increase, and net income of $61.6 million. The company highlights strong user engagement, including over 1 million quarterly active prescribers and significant adoption of its new AI products. Doximity also provided financial guidance for the upcoming fiscal quarter and updated its fiscal year outlook, alongside authorizing a new $500 million stock repurchase program.

https://www.businesswire.com/news/home/20260205969285/en/Doximity-Announces-Fiscal-2026-Third-Quarter-Financial-Results

Doximity Q3 2026 earnings preview

This article provides a preview of Doximity's Q3 2026 earnings. It is a brief, placeholder article from MSN, indicating that more detailed information would typically follow such an announcement.

https://www.msn.com/en-us/money/markets/doximity-q3-2026-earnings-preview/ar-AA1VGkrZ?ocid=finance-verthp-feeds

Why Doximity (DOCS) Is Down 10.5% After AI Disruption Fears Hit Tech-Health Software Stocks

Doximity's stock has dropped 10.5% due to investor concerns about AI potentially disrupting tech-health software, despite analysts expecting revenue growth and strong customer expansion. While fears of AI disruption and rich valuation are risks, the company's fiscal 2026 revenue guidance, large account expansion, and a significant share buyback program still present a positive investment narrative. Investors are encouraged to consider multiple perspectives on Doximity's valuation and risk profile given the current market sentiment.

https://www.sahmcapital.com/news/content/why-doximity-docs-is-down-105-after-ai-disruption-fears-hit-tech-health-software-stocks-2026-02-04

Trending Today

Bausch + Lomb ($BLCO) Stock Forecast: Up 5.0% Today

Campbell Soup Company ($CPB) Stock Forecast: Down 6.3% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Down 5.2% Today

Lamb Weston Holdings Inc. ($LW) Stock Forecast: Down 5.6% Today

Norwegian Cruise Line Holdings Ltd. ($NCLH) Stock Forecast: Up 5.0% Today

Crocs Inc. ($CROX) Stock Forecast: Up 5.1% Today

Credo Technology Group ($CRDO) Stock Forecast: Up 5.1% Today

Leidos Holdings Inc. ($LDOS) Stock Forecast: Down 6.3% Today

Chegg Inc. ($CHGG) Stock Forecast: Down 5.5% Today

H&R Block Inc. ($HRB) Stock Forecast: Down 5.1% Today

Doximity, Inc. Price History

03.01.2026 - DOCS Stock was down 7.7%

• The analysis of liquidity mapping around DOCS price events suggests weak sentiment and supports a short bias, indicating a bearish outlook for the stock.
• Three distinct trading strategies all point towards downside risk for DOCS, reinforcing the bearish movement observed in the market today.
• The elevated downside risk highlighted in the analysis, along with the specific entry, target, and stop-loss levels, likely contributed to the strong bearish movement in DOCS today.

06.01.2026 - DOCS Stock was down 24.2%

• Strong Q3 financial results were reported by Doximity, surpassing revenue and EPS expectations. However, the stock faced a decline following a less optimistic revenue forecast for the upcoming fiscal fourth quarter.
• Amid investor apprehensions regarding AI disruptions in tech-health software, there was a 10.5% decrease in Doximity's stock value. This was despite positive indicators such as revenue growth, increased customer base, and the initiation of a new stock repurchase plan.
• Emerging AI models from Anthropic and OpenAI resulted in a sharp drop in tech company stocks like Doximity, reflecting concerns of potential interference from autonomous AI agents in conventional software services.
• AI analyses on Doximity's stock have indicated subdued sentiment, supporting a short stance, and hinting at significant downside risks for DOCS within the present market conditions.

08.07.2025 - DOCS Stock was up 12.4%

• Doximity's stock experienced a strong bullish movement following its Q1 earnings report, where it surpassed revenue and earnings expectations. This positive performance likely boosted investor confidence in the company's growth prospects.
• Despite a decrease in gross margin, the overall revenue growth and raised full-year forecast contributed to the stock's upward momentum.
• The acquisition of Pathway Medical for $63 million to enhance doctors' access to AI-powered clinical reference tools could have also fueled optimism among investors about Doximity's future expansion and innovation in the healthcare sector.
• The unusual options activity showing a majority of traders taking bullish positions further indicates a positive sentiment surrounding Doximity's stock, potentially driving its upward trajectory.

08.07.2025 - DOCS Stock was up 13.3%

• Earnings for the first quarter exceeded analyst expectations significantly, leading to a positive impact on the company's stock performance.
• The acquisition of Pathway Medical for $63 million aims to improve doctors' access to AI-powered clinical reference tools, demonstrating Doximity's focus on expanding its services and embracing technological advancements in healthcare.
• Strong interest in bullish options trading indicates a positive outlook on Doximity, reflecting confidence in the company's future.
• The combination of strong earnings, strategic acquisitions, and positive market sentiment likely drove DOCS to experience significant bullish movement.

05.00.2026 - DOCS Stock was up 5.0%

• The uptrend in DOCS may be linked to insights on real-time signal analysis and trading strategies that suggested a neutral short-term outlook, potentially enticing more investors to participate.
• The recent settlement of an investor class-action lawsuit could have offered a sense of closure and transparency, bolstering investor confidence and propelling the stock value upwards.
• In summary, the positive trading strategies and legal resolution may have both played a role in driving the bullish movement in DOCS for the day.

10.09.2025 - DOCS Stock was down 5.7%

• The bearish movement in DOCS could be attributed to a broader negative sentiment in the healthcare sector, as evidenced by the downgrades in other healthcare companies like Allogene Therapeutics and Akero Therapeutics.
• The change in analyst outlook for DOCS may have raised concerns among investors, leading to selling pressure on the stock.
• It is possible that investors are reevaluating their positions in healthcare technology companies, leading to a shift away from previously bullish stocks like DOCS.

21.10.2025 - DOCS Stock was up 7.5%

• The positive movement in DOCS stock today could be linked to Hims & Hers (HIMS) broadening its connected care model, indicating a rising trend towards telemedicine and digital health services.
• The introduction of new diagnostics, hormonal health services, and at-home testosterone treatments by HIMS might have boosted investor confidence in companies like DOCS operating in the telehealth sector.
• This development implies a consistent emphasis on innovation and expansion in the digital healthcare domain, which is advantageous for companies like DOCS that lead in offering convenient and accessible healthcare services online.

07.10.2025 - DOCS Stock was down 10.2%

• The options market activity indicating a bearish position on Doximity suggests that institutional investors are pessimistic about the company's short-term prospects.
• This bearish sentiment could be driven by concerns over Doximity's growth potential, competitive pressures, or overall market conditions impacting the healthcare technology sector.
• Retail traders should take note of this development and consider potential downside risks when evaluating their investment decisions in Doximity.

07.10.2025 - DOCS Stock was down 14.6%

• Despite surpassing expectations with positive Q2 earnings and higher revenues, the stock plummeted by close to 9% in pre-market trading, showcasing a divergence between company performance and investor outlook.
• The large drop in the stock, influenced by the bearish stance of well-resourced investors according to options market data, indicates wavering confidence in Doximity's future trajectory, resulting in the stock's decline.
• The disparity between robust financial outcomes and the market's pessimistic response may be linked to overarching market conditions, specific challenges within the sector, or uncertainties surrounding Doximity's sustained growth in the healthcare technology field.

30.08.2025 - DOCS Stock was down 5.2%

• Concerns about Doximity's competitive position in the digital health sector arose due to comparisons with Hims & Hers, potentially impacting investor sentiment negatively.
• Representative Jonathan Jackson's substantial purchase of Doximity stock raised questions among investors, possibly leading to a sell-off amid concerns of insider trading or lack of confidence in the company.
• Activity in the options market hinted at a possible shift in sentiment towards Doximity stock, contributing to the bearish trend as traders likely sought to hedge against further downside risk.

03.09.2025 - DOCS Stock was up 5.3%

• DOCS stock demonstrated a robust bullish trend, surpassing the market performance.
• Speculations surrounding Doximity's growth prospects and platform expansion, particularly in contrast to Hims & Hers, attracted investors' attention.
• The optimistic market outlook towards companies in the healthcare technology industry, including Doximity, likely influenced the strong bullish movement in DOCS stock.

10.01.2026 - DOCS Stock was up 5.0%

• After exceeding expectations in revenue and EPS for Q3, Doximity's shares experienced a significant drop following a conservative revenue outlook for the fiscal fourth quarter, leading to a bearish trend in the market.
• The stock's recent decline is linked to industry-wide apprehensions regarding the impact of AI technology in the tech-health software segment, despite noteworthy growth in revenue, expansion of customer base, and initiation of a new stock repurchase plan.
• The disparity between Doximity's robust historical performance, subdued future growth projections, and elevated P/E ratio has heightened investment risks, contributing to the downward trajectory of the stock.
• In conclusion, while facing challenges related to market sentiment and valuation uncertainties, Doximity's strategic endeavors such as integrating AI products and enhancing user engagement may present favorable long-term investment prospects.